SSBMT Saudi Society of Blood & Marrow Transplantation الجمعية السعودية لزراعة الدم ونخاع العظام
  • Home
  • Conference
    • 2026 Conference
    • Previous Events

    • Gallery
  • Membership
  • Research
  • Registry
  • About
    • About SSBMT
    • Board & Committees
    • Awards
    • Sponsorships
    • Partners

    • Training
    • Publications
  • Contact
  • Member Login
  • عر

Conference Gallery

Photos and videos from SSBMT Annual Conferences.

Videos
1 Integration of Menin Inhibitors in the therapy of AML | Muteb Althomali | | 30 JAN 2026
1 Integration of Menin Inhibitors in the therapy of AML | Muteb Althomali | | 30 JAN 2026
Philadelphia positive ALL -Best First Line Therapy | Nahla Shihata | 30 JAN 2026
Philadelphia positive ALL -Best First Line Therapy | Nahla Shihata | 30 JAN 2026
CAR-T vs Bispecific Antibodies in Aggressive Lymphoma | Sameer Alamoudi | 30 JAN 2026
CAR-T vs Bispecific Antibodies in Aggressive Lymphoma | Sameer Alamoudi | 30 JAN 2026
Now Is the Time to Improve Outcomes in Diffuse Large B-Cell Lymphoma | Mubarak Almansour| 30JAN 2026
Now Is the Time to Improve Outcomes in Diffuse Large B-Cell Lymphoma | Mubarak Almansour| 30JAN 2026
Is there still a role for ASCT in Mantle Cell Lymphoma | Reyad Dada | 30 JAN 2026
Is there still a role for ASCT in Mantle Cell Lymphoma | Reyad Dada | 30 JAN 2026
HIV Associated Lymphomas | Hafiz Malhan | 30 JAN 2026
HIV Associated Lymphomas | Hafiz Malhan | 30 JAN 2026
Frontline Management in Multiple Myeloma | Ayman Alhejazi | 30 JAN 2026
Frontline Management in Multiple Myeloma | Ayman Alhejazi | 30 JAN 2026
ALL:How does the future look like w/ Incorporation of upfront Novel therapies | Saleem Eldadah
ALL:How does the future look like w/ Incorporation of upfront Novel therapies | Saleem Eldadah
CAR-T vs Bispecific Antibodies in Myeloma—Bridging Strategies& supportive measures|Abdullah Alsaleh
CAR-T vs Bispecific Antibodies in Myeloma—Bridging Strategies& supportive measures|Abdullah Alsaleh
MRD Negativity in Multiple Myeloma: A New Treatment Endpoint| Ghazi Alotaibi | 30 JAN 2026
MRD Negativity in Multiple Myeloma: A New Treatment Endpoint| Ghazi Alotaibi | 30 JAN 2026
Plasma Cell Leukemia – Update on therapy SOC | Majed Alahmadi | 30 JAN 2026
Plasma Cell Leukemia – Update on therapy SOC | Majed Alahmadi | 30 JAN 2026
Emerging role of BCMA targeting in management of RRMM | Ghazi Alotaibi | 30 JAN 2026
Emerging role of BCMA targeting in management of RRMM | Ghazi Alotaibi | 30 JAN 2026
Gene Therapies: A New Era in Hemoglobinopathies | Ihab Elehmaidi | 30 JAN 2026
Gene Therapies: A New Era in Hemoglobinopathies | Ihab Elehmaidi | 30 JAN 2026
Gene Therapy for SCD and TDT — Clinical and Economic Reality | Mohsen Alzahrani | 30 JAN 2026
Gene Therapy for SCD and TDT — Clinical and Economic Reality | Mohsen Alzahrani | 30 JAN 2026
Managing Challenging Cases: Sickle Cell disease | Gad Allah Ali | 30 JAN 2026
Managing Challenging Cases: Sickle Cell disease | Gad Allah Ali | 30 JAN 2026
Emerging Therapies in β-Thalassemia — Luspatercept and Beyond | Abdullah Alzayed | 30 JAN 2026
Emerging Therapies in β-Thalassemia — Luspatercept and Beyond | Abdullah Alzayed | 30 JAN 2026
Challenges in Thalassemia for Precision Medicine: Evidence Based Research| Soad Aljaouni|30 JAN 2026
Challenges in Thalassemia for Precision Medicine: Evidence Based Research| Soad Aljaouni|30 JAN 2026
CML 2025:Achieving Treatment-Free Remission—Patient Selection Algorithm | Ihab Elhemaidi |30JAN 2026
CML 2025:Achieving Treatment-Free Remission—Patient Selection Algorithm | Ihab Elhemaidi |30JAN 2026
MPNs: JAK Inhibitors vs New Pathway Inhibitors— When to Switch Therapy | Sultan Altouri |30 JAN 2026
MPNs: JAK Inhibitors vs New Pathway Inhibitors— When to Switch Therapy | Sultan Altouri |30 JAN 2026
GVHD 2025: New Predictive Biomarkers and Treatment Algorithms | Naif Aljohani | 30 JAN 2026
GVHD 2025: New Predictive Biomarkers and Treatment Algorithms | Naif Aljohani | 30 JAN 2026
Eosinophilic Updates to Old Approaches | Osman Radhwi | 30 JAN 2026
Eosinophilic Updates to Old Approaches | Osman Radhwi | 30 JAN 2026
Neutrophilia other than CML | Hanan Hamed | 31 JAN 2026
Neutrophilia other than CML | Hanan Hamed | 31 JAN 2026
Fixed duration Novel agents’ combinations in CLL upfront therapy | Ahmed Absi | 31 JAN 2026
Fixed duration Novel agents’ combinations in CLL upfront therapy | Ahmed Absi | 31 JAN 2026
Hodgkin Lymphoma–therapy sequencing in the era of upfront biologic therapy |Ahmed Barefah |31JAN2026
Hodgkin Lymphoma–therapy sequencing in the era of upfront biologic therapy |Ahmed Barefah |31JAN2026
Richter’s Transformation | Mohammed Almakadi | 31 JAN 2026
Richter’s Transformation | Mohammed Almakadi | 31 JAN 2026
Complicated cases of thrombosis – challenges in management | Ashraf Warsi | 31 JAN 2026
Complicated cases of thrombosis – challenges in management | Ashraf Warsi | 31 JAN 2026
Cancer Associated Thrombosis (CAT) | Sarah Sewaralthahab | 31 JAN 2026
Cancer Associated Thrombosis (CAT) | Sarah Sewaralthahab | 31 JAN 2026
Overview on Platelets Products in Clinical Practice | Salwa Hindawi | 31 JAN 2026
Overview on Platelets Products in Clinical Practice | Salwa Hindawi | 31 JAN 2026
Lymphoma mimickers & Diagnostic Traps | Alfadel Alshaibani | 31 JAN 2026
Lymphoma mimickers & Diagnostic Traps | Alfadel Alshaibani | 31 JAN 2026
Photos
Gallery photo
Gallery photo
Gallery photo
Gallery photo
Gallery photo
Gallery photo
Gallery photo
Gallery photo
Gallery photo
Gallery photo
Gallery photo
Gallery photo
SSBMT

The Saudi Society of Blood and Marrow Transplantation advances hematology and transplant medicine across the Kingdom through education, research, and collaboration.

𝕏 ▶
Society
About Us Board & Committees Awards Sponsorships Partners Bylaws Contact
Resources
2026 Conference Previous Events Gallery Membership Research Registry Training Publications
Contact

Saudi Society of Blood & Marrow Transplantation (SSBMT)
MC 1515 | Ministry of National Guard Health Affairs
P.O. Box 22490 Riyadh 11426
Direct Line: +966-11-429-4508
ssbmt@mngha.med.sa
ssbmt1@gmail.com


© 2026 Saudi Society of Blood & Marrow Transplantation. All rights reserved.
Privacy Policy | Terms of Use